Benralizumab
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
- Benralizumab
- Pharmacist Assessment Report
- Benralizumab: Anti-IL-5 receptor α monoclonal antibody → Thrombocytopenia due to immune destruction
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Benralizumab: Anti-IL-5 receptor α monoclonal antibody → Thrombocytopenia due to immune destruction
One-Sentence Summary
Benralizumab is an anti-IL-5 receptor alpha antibody that depletes eosinophils and basophils. The TxGNN model predicts it may be effective for thrombocytopenia due to immune destruction, but this is a computational prediction only: 0 clinical trials and 0 publications currently support it directly.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Thrombocytopenia due to immune destruction |
| TxGNN Prediction Score | 0.9934 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available in the data compiled for this report. From what is known, benralizumab targets the IL-5 receptor alpha subunit (IL5RA) and depletes eosinophils and basophils through antibody-dependent cell-mediated cytotoxicity (ADCC).
The link to immune thrombocytopenia is speculative. Eosinophil-driven inflammation is not an established driver of platelet destruction, which is mainly mediated by autoantibodies and related immune mechanisms. The high score reflects a model-based association rather than a demonstrated biological or clinical rationale.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02496135 | FASENRA PEN | Not recorded | Not recorded |
| 02473232 | FASENRA | Not recorded | Not recorded |
Safety Considerations
- Drug Interactions: The only interaction record is a pharmacology entry for the drug’s own target, the interleukin-5 receptor alpha subunit. It is not a drug–drug interaction.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a high model score but no supporting clinical trials or publications for this disease, and the mechanistic link is weak. The evidence level is L5.
To proceed, the following is needed:
- Mechanistic or preclinical evidence that IL-5Rα–directed eosinophil/basophil depletion affects platelet destruction
- Case series or observational data on benralizumab in immune thrombocytopenia
- Package insert warnings and contraindications from Health Canada
- Detailed mechanism-of-action data
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.